Case Number:

IPR2023-00722

Case Type:

IPR

Status:

Institution Denied

Petitioner:

Mylan Pharmaceuticals Inc. et al.

Patent Owner:

Tech Center:

1. Filed: March 16, 2023 00:00

   Coverage

   1. October 03, 2023

      Novo Nordisk Dodges PTAB Review On Lucrative Ozempic IP

      The Patent Trial and Appeal Board will not review whether a pair of Novo Nordisk patents covering its blockbuster diabetes and weight-loss drug Ozempic should be invalidated. 

   ---

   Stay ahead of the curve

   In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

   
   

   • Search PTAB cases and full-text documents.
   • Download filings with the U.S. Patent & Trademark Office’s Patent Trial & Appeal Board.
   • Set up alerts on new cases, follow ongoing cases, track new decisions and so much more!

   TRY LAW360 FREE FOR SEVEN DAYS

   View the PTAB case documents

   Already a subscriber? Click here to login